Asset Details
Do you wish to reserve the book?
Vandetanib
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Vandetanib
Do you wish to request the book?
Vandetanib
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Vandetanib
2011
Overview
Vandetanib is an orally active antagonist of vascular endothelial growth factor (VEGF) receptor-2 (VEGFR-2), epidermal growth factor receptor (EGFR or HER1 or ErbB1) and RET kinase, and is now available in the US for the treatment of metastatic medullary thyroid cancer (MTC). Regulatory submissions for this indication have been filed in the EU and Canada, with clinical development in malignant MTC ongoing in several other countries. Vandetanib is being developed by AstraZeneca, and is also in phase II development for biliary, breast and prostate cancer. Earlier, AstraZeneca withdrew regulatory filings for non-small cell lung cancer (NSCLC) in the US and EU, and later discontinued development. This article summarizes the milestones in the development of vandetanib leading to this first approval in malignant MTC.
Publisher
Springer International Publishing,Adis International,Wolters Kluwer Health, Inc
Subject
/ Antineoplastic Agents - adverse effects
/ Antineoplastic Agents - pharmacology
/ Antineoplastic Agents - therapeutic use
/ Biological and medical sciences
/ Humans
/ Medicine
/ Pharmacology. Drug treatments
/ Piperidines - adverse effects
/ Piperidines - therapeutic use
/ Quinazolines - adverse effects
/ Quinazolines - therapeutic use
/ Thyroid Neoplasms - drug therapy
/ Thyroid Neoplasms - pathology
/ Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors
